Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension

QR Code

Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension

Aim. To assess atorvastatin lipid-lowering effect and tolerability at the initial stage of lipid-lowering treatment. Material and methods. The study included 47 patients (14 women, 33 men; mean age 55,6±11,6 years). Inclusion criteria were: verified coronary heart disease, CHD (stable effort angina,...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. B. Amirov, M. V. Potapova, F. I. Ishkineev, G. V. Tukhvatullina, N. G. Efimova, L. F. Mingazutdinova
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 1970-01-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	dyslipidemia coronary heart disease lipid-lowering therapy atorvastatin
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1480
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Atorvastatin effectiveness in dyslipidemia correction among coronary heart disease and arterial hypertension patients with high risk of cardiovascular complications
by: E. V. Minakov, et al.
Published: (2007-10-01)

Effectiveness, safety, and endothelial function effects of atorvastatin lipid-lowering therapy in coronary heart disease patients undergoing percutaneous coronary intervention
by: M. P. Mal’gina, et al.
Published: (2007-06-01)

Randomized «FARVATER» study. Atorvastatin (10 and 20 mg/d) in treating patients with coronary heart disease and dyslipidemia: effects on lipids, C-reactive protein and fibrinogen levels
by: A. V. Susekov, et al.
Published: (2006-12-01)

USING A COMBINATION OF PERINDOPRIL, INDAPAMIDE AND ROSUVASTATIN IN THE TREATMENT OF PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA
by: O. M. Drapkina, et al.
Published: (2017-09-01)

Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness
by: A. V. Susekov, et al.
Published: (2007-06-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
by: N. G. Gogolashvili
Published: (2015-09-01)

Long-term low-dose atorvastatin therapy and prevention of macroangiopathy complications in elderly patients with Type 2 diabetes mellitus
by: G. A. Batrak, et al.
Published: (2010-06-01)

Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
by: M. V. Ezhov, et al.
Published: (2025-06-01)

Aggressive statin therapy in acute coronary syndrome: therapeutic potential of atorvastatin in the daily dose of 80 mg
by: A. N. Britov
Published: (2009-12-01)

Dose-dependent effects of atorvastatin in the hospitalisation period of myocardial infarction
by: O. L. Barbarash, et al.
Published: (2013-06-01)

Atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis: comparison, contrast, and differentiated therapy
by: L. B. Lazebnik, et al.
Published: (2009-06-01)

RECENT ADVANCES IN THE APPLICATION OF HIGH DOSES OF ATORVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE
by: M. V. Ezhov
Published: (2016-01-01)

Possibilities of atorvastatin loading dose using for the prevention of perioperative myocardial damage in patients with stable coronary artery disease
by: A. S. Ragozina, et al.
Published: (2019-11-01)

Lipid and pleiotropic effects of atorvastatin in patients with high cardiovascular risk
by: R. S. Karpov, et al.
Published: (2009-08-01)

Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome
by: Sh. A. Mostafa, et al.
Published: (2018-11-01)

New methods for dyslipidemia correction
by: V. T. Ivashkin, et al.
Published: (1970-01-01)

SPECIFICS OF LIPID METABOLISM AND ATORVASTATIN EFFICACY IN TYPE 2 DIABETES WITH CARRIAGE OF VARIOUS POLYMORPHISMS OF CHOLESTEROL ETHER CARRYING PROTEIN TaqIB GENE
by: M. V. Kim, et al.
Published: (2015-10-01)

Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin)
by: R. G. Oganov, et al.
Published: (2006-12-01)

Pathophysiological rationale for the results of atherogenic dyslipidemia simulation in rats
by: V. G. Banzaraksheev
Published: (2016-05-01)

Potential of combination therapy in patients with hypertension and dyslipidemia
by: T. V. Gorokhova, et al.
Published: (2022-08-01)

ACUTE ATORVASTATIN RECAPTURE THERAPY IN CORONARY ARTERY BYPASS GRAFTING
by: A. V. Panov, et al.
Published: (2017-07-01)

Associations of polyphenolic compounds consumption and the risk of dyslipidemia in the Siberian population
by: T. I. Batluk, et al.
Published: (2020-06-01)

Lipid and pleiotropic effects of atorvastatin in patients with acute coronary syndrome
by: A. A. Yalymov, et al.
Published: (1970-01-01)

Anti-inflammatory effects of low- and high-dose atorvastatin therapy in patients with coronary heart disease and rheumatoid arthritis
by: V. S. Tutunov, et al.
Published: (2008-10-01)

Dyslipidemia and Hypertension Among Type 2 Diabetics at a Tertiary Care Hospital of South Gujarat, India
by: Jash Kotak, et al.
Published: (2025-06-01)

The role of constipation in the development of dyslipidemia in the elderly
by: A. V. Martynenko, et al.
Published: (2025-06-01)

Statins in acute coronary syndrome
by: O. M. Drapkina
Published: (2009-10-01)

Analysis of the binary mixtures of amlodipine and atorvastatin by chemometric-spectophotometric method
by: Hayrettin Bulum, et al.
Published: (2025-06-01)

ATORVASTATIN — 20 YEARS IN THE STRUGGLE FOR LIFE
by: N. G. Gogolashvili
Published: (2018-03-01)

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES
by: A. N. Meshkov
Published: (2016-01-01)

Levels of serum per- and polyfluoroalkyl substances and association with dyslipidemia in the Korean population
by: Kangyeon Park, et al.
Published: (2025-09-01)

EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA
by: J. E. Semyonova, et al.
Published: (2015-12-01)

Evaluating the effect of mobile applications “My A:Care” and “Smart Coach” on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical study
by: Chatlert Pongchaiyakul, et al.
Published: (2025-07-01)

Levothyroxine therapy and its impact on serum lipids: Addressing dyslipidemia in hypothyroidism
by: Rohit Kumar Gupta, et al.
Published: (2025-06-01)

Nephroprotective effect of atorvastatin at a dose of 80 mg in patients with ST-segment elevation myocardial infarction with an invasive treatment strategy
by: A. D. Gavrilko, et al.
Published: (2023-11-01)

Assessment of lipid profile when using lipid-lowering therapy (statins) in patients with coronary atherosclerosis
by: N. E. Gavrilova, et al.
Published: (2015-11-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

Aorta and brachiocephalic artery pathology in dyslipidemia
by: B. M. Lipovetsky
Published: (2005-06-01)

Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)
by: M. V. Kim, et al.
Published: (2015-03-01)

Efficacy of atorvastatin therapy in prevention of postoperative atrial fibrillation in patients with ischemic heart disease
by: O. A. Rubanenko
Published: (2015-11-01)